The test monitors circulating tumor DNA without requiring tumor tissue profiling, with clinical study findings showing detection of disease progression a median of 7.4 months before imaging.
A study of 60,449 lab results found that using broader screening thresholds doubled detection rates of primary aldosteronism compared to Endocrine Society guidelines, according to research in Hypertension.
Abbott’s Oncodetect MRD test showed a 30% sensitivity improvement over existing methods for detecting colorectal cancer recurrence post-surgery, according to clinical data presented at ESMO 2026.
The Signals LabGistics tool translates standard operating procedures into scientific workflows and supports GxP compliance across laboratory environments.
Labcorp plans to offer the HPV test through clinician-collected and self-collected screening options beginning in late 2026, providing extended genotyping to help guide cervical cancer risk assessment.
